Last reviewed · How we verify

Short-term Sintilimab

Shanghai Jiao Tong University School of Medicine · FDA-approved active Small molecule Under review Quality 0/100

Short-term Sintilimab is a PD-1 inhibitor Small molecule drug developed by Shanghai Jiao Tong University School of Medicine. It is currently FDA-approved for Hodgkin lymphoma, Non-small cell lung cancer, Gastric cancer.

Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.

Sintilimab is an antibody that acts as a programmed cell death protein 1 antagonist. It is being studied in combination with taxane and carboplatin for neoadjuvant therapy in triple-negative breast cancer, as well as in rectal cancer, among other conditions.

At a glance

Generic nameShort-term Sintilimab
SponsorShanghai Jiao Tong University School of Medicine
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

Sintilimab binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with PD-L1 and PD-L2 ligands expressed by tumor cells and immune cells. This blockade restores anti-tumor immune responses by reactivating exhausted T cells. The drug is used in short-term treatment regimens for various malignancies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Short-term Sintilimab

What is Short-term Sintilimab?

Short-term Sintilimab is a PD-1 inhibitor drug developed by Shanghai Jiao Tong University School of Medicine, indicated for Hodgkin lymphoma, Non-small cell lung cancer, Gastric cancer.

How does Short-term Sintilimab work?

Sintilimab is a monoclonal antibody that blocks PD-1 on immune cells, allowing them to recognize and attack cancer cells.

What is Short-term Sintilimab used for?

Short-term Sintilimab is indicated for Hodgkin lymphoma, Non-small cell lung cancer, Gastric cancer, Esophageal squamous cell carcinoma.

Who makes Short-term Sintilimab?

Short-term Sintilimab is developed and marketed by Shanghai Jiao Tong University School of Medicine (see full Shanghai Jiao Tong University School of Medicine pipeline at /company/shanghai-jiao-tong-university-school-of-medicine).

What drug class is Short-term Sintilimab in?

Short-term Sintilimab belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is Short-term Sintilimab in?

Short-term Sintilimab is FDA-approved (marketed).

What are the side effects of Short-term Sintilimab?

Common side effects of Short-term Sintilimab include Fatigue, Decreased appetite, Nausea, Immune-related adverse events (pneumonitis, hepatitis, colitis), Infusion-related reactions.

What does Short-term Sintilimab target?

Short-term Sintilimab targets PD-1 and is a PD-1 inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing